Vilin Bio Med Ltd
Incorporated in 2005, Vilin Bio Med Ltd is in the business of manufacturing and selling of pharmaceutical products[1]
- Market Cap ₹ 62.7 Cr.
- Current Price ₹ 41.1
- High / Low ₹ 54.4 / 19.0
- Stock P/E 32.5
- Book Value ₹ 18.6
- Dividend Yield 0.00 %
- ROCE 10.8 %
- ROE 7.51 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.92%
- Company has a low return on equity of 3.53% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 16.62 | 11.54 | 11.21 | 12.31 | 15.80 | 14.81 | 42.26 | |
| 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 39.06 | |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 3.20 |
| OPM % | 5.48% | 7.45% | 6.87% | 20.96% | 5.25% | 5.33% | 7.57% |
| 0.01 | 0.00 | 0.00 | 0.02 | 0.32 | 0.47 | 0.00 | |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.07 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.10 | 0.28 |
| Profit before tax | 0.20 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 2.85 |
| Tax % | 20.00% | 25.00% | 25.00% | 30.34% | 26.09% | 25.81% | 31.93% |
| 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 | |
| EPS in Rs | 0.48 | 0.36 | 0.09 | 1.26 | 0.11 | 0.16 | 1.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 51% |
| TTM: | 185% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 74% |
| 3 Years: | 16% |
| TTM: | 777% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| 1 Year: | 75% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.30 | 3.30 | 3.30 | 9.95 | 13.95 | 13.95 | 15.25 |
| Reserves | 3.94 | 4.06 | 4.10 | 0.73 | 8.89 | 9.11 | 13.12 |
| 4.53 | 5.52 | 5.30 | 4.93 | 6.83 | 2.57 | 0.21 | |
| 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.10 | 6.36 | |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.73 | 34.94 |
| 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 2.87 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.88 | 32.07 | |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.73 | 34.94 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -1.46 | -1.00 | 0.21 | -1.66 | -7.42 | 0.22 | 0.70 | |
| -0.02 | 0.00 | 0.00 | -0.03 | 0.32 | -1.11 | -0.30 | |
| 1.51 | 0.98 | -0.22 | 1.68 | 8.87 | -5.10 | 1.01 | |
| Net Cash Flow | 0.03 | -0.02 | -0.01 | 0.00 | 1.77 | -5.99 | 1.41 |
| Free Cash Flow | -1.48 | -1.00 | 0.21 | -1.69 | -7.42 | -1.35 | 0.40 |
| CFO/OP | -156% | -112% | 29% | -43% | -888% | 37% | 49% |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 159.66 | 241.96 | 253.64 | 166.04 | 131.22 | 155.51 | 137.85 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125.41 | 119.50 | 70.03 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 37.67 | 32.49 |
| Cash Conversion Cycle | 166.31 | 292.03 | 321.13 | 150.28 | 201.91 | 237.35 | 175.38 |
| Working Capital Days | 110.91 | 204.32 | 211.64 | 45.07 | 76.23 | 195.44 | 168.16 |
| ROCE % | 4.87% | 4.30% | 17.17% | 4.51% | 4.20% | 10.77% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Capital Work in Progress (Capacity Expansion) Rs. Lakhs |
|
|||
| Cost of Materials Consumed (Raw Material Volume) Rs. Lakhs |
||||
| Employee Benefits Expense (Workforce) Rs. Lakhs |
||||
| Finished Goods Inventory (Production Output Held) Rs. Lakhs |
||||
| Electricity Consumption (Manufacturing Activity) units |
||||
Extracted by Screener AI
Documents
Announcements
-
Copy of Newspaper Publication
- Published newspaper ads for notice of Vilin Bio Med's 20th Annual General Meeting on August 13, 2026.
-
General Updates
- NSE issued no-objection for Chemgenix Laboratories’ amalgamation into Vilin Bio Med on August 10, 2026.
-
Outcome of Board Meeting
- Board approved AGM notice, appointed secretarial auditor, and fixed 20th AGM on September 2, 2026.
-
Updates
- Vilin Bio Med registered as Manufacturer Exporter with Pharmexcil, aiding export expansion.
-
General Updates
- Vilin Bio Med signed an MOU with Ideal Pharma BV on July 29, 2026 for European medicine distribution.
Business Overview:[1][2]
VBML is an ISO-9001-2008 & GMP certified manufacturer of Pharmaceutical formulations' viz. Oral Liquid (Syrups/Suspensions/Dry Powders (βeta & Non βeta-Lactam), Tablets & Capsules (βeta & Non βeta-Lactam), External Preparations, etc. It sells its products in bulk to Pharmaceuticals Manufacturers, Marketers and Traders. Company does not sell products under any brand name